Publication at First Faculty of Medicine |
2022
Abstract
In the treatment of metastatic renal cell carcinoma, treatment options have expanded significantly in recent years. The current standard is the administration of tyrosine kinase inhibitors, a more recent procedure is the administration of immunotherapy focused on the control points of the immune response.
Recently, it has been shown that combination therapy could have a more significant effect. One possibility is the combination of the tyrosine kinase inhibitor axitinib with the monoclonal antibody avelumab.
This antibody inhibits the immune response checkpoints and results in the activation of the immune system. The review article deals with the current position of this combination in the treatment of first-line metastatic kidney cancer.